论文部分内容阅读
目的探讨苯甲酸雌二醇在克罗米芬促排卵周期中的的作用及用药安全性。方法将80例多囊卵巢综合征患者随机分成2组,两组患者从月经第5天开始口服克罗米芬50mg/d,连用5d;观察组40例在基础治疗方案上加肌内注射苯甲酸雌二醇6～8mg,对照组40例在基础治疗方案上加口服戊酸雌二醇片,2mg/次,1次/d。比较两组成熟卵泡数、子宫内膜厚度、排卵情况;血清性激素(FSH、LH、T)的水平;随访一年半后,比较两组新生儿的数量、体重。结果观察组成熟卵泡数目、子宫内膜厚度、排卵率高于对照组(P<0.05),随访1年后,观察组临床妊娠率高于对照组(P<0.05),两组患者LH、T均有不同程度的下降,观察组患者下降更明显,两组患者FSH均有不同程度的上升。观察组对血清性激素的改善情况优于对照组,两组患者比较差异有统计学意义(P<0.05);两组新生儿的Apart’s评分有统计学差异(P<0.05),观察组优于对照组。结论甲酸雌二醇能在克罗米芬促排卵周期中有理想促进作用,临床建议推广运用。
Objective To investigate the role and safety of estradiol benzoate in clomiphene and ovulation induction cycles. Methods Eighty patients with PCOS were randomly divided into two groups. Clomiphene citrate (50 mg / d) was administered orally from the fifth day of menstruation for 5 days. Forty patients in the observation group received intramuscular injection of benzoate Diol 6 ~ 8mg, 40 cases of the control group on the basis of treatment programs plus oral valerate valerate tablets, 2mg / time, 1 / d. The number of mature follicles, endometrial thickness and ovulation were compared between the two groups. The levels of serum sex hormones (FSH, LH, T) were compared. One year and a half after follow-up, the number and weight of newborns were compared. Results The number of mature follicles, endometrial thickness and ovulation rate in the observation group were significantly higher than those in the control group (P <0.05). After one year of follow-up, the clinical pregnancy rate in the observation group was higher than that in the control group (P <0.05) All with different degrees of decline, the observation group patients decreased more obviously, both groups of patients with FSH increased in varying degrees. The improvement of serum sex hormones in the observation group was better than that in the control group, and there was significant difference between the two groups (P <0.05). There was a significant difference in the two groups (P <0.05). The observation group was better than the control group group. Conclusions Estradiol formate can promote the ovulation cycle in clomiphene, and its clinical recommendations are promoted.